Human papillomavirus (HPV) infection, cervical cancer and vaccination against HPV: A Nordic perspective

Acta Obstetricia et Gynecologica Scandinavica

Volumn 86, Issue 11, 2007, Pages 1286-1289

  Kjær, Susanne Krüger ^a,b  

^a Rigshospitalet   (Denmark)

^b INSTITUTE OF CANCER EPIDEMIOLOGY   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

WART VIRUS VACCINE;

CANCER SCREENING; CLINICAL TRIAL; CONDYLOMA; HUMAN; IMMUNE RESPONSE; IMMUNIZATION; NOTE; PRIORITY JOURNAL; UTERINE CERVIX CANCER; VACCINATION; VERRUCA VULGARIS; VIRUS IDENTIFICATION; WART VIRUS;

ADOLESCENT; ADULT; CHILD; FEMALE; HUMANS; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; SCANDINAVIA; UTERINE CERVICAL NEOPLASMS;

EID: 35649027501     PISSN: 00016349     EISSN: 16000412     Source Type: Journal    
DOI: 10.1080/00016340701698781     Document Type: Note

References (26)

1. Parkin DM, Bray F. Chapter 2: the burden of HPV-related cancers. Vaccine. 2006;24(suppl 3):S11-25.
2. Nordcan; Available online at: www.ancr.nu/nordcan.asp
3. Nohr B, Tabor A, Frederiksen K, Kjaer SK. Loop electrosurgical excision of the cervix and the subsequent risk of preterm delivery. Acta Obstet Gynecol Scand. 2007;86:596-603.
4. Walboomers JM, Jacobs MV, Manos MM, Bosch XF, Kummer JA, Shah KV. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999;189:12-9.
5. Burchell AN, Winer RL, de Sanjosé R, Franco EL. Chapter 6. Epidemiology and transmission dynamics of genital HPV infection. Vaccine. 2006;24(suppl 3):S52-61.
6. Trottier H, Franco EL. The epidemiology of genital human papillomavirus infection. Vaccine. 2006;24(Suppl 1):4-15.
7. Moscicki AB, Schiffman M, Kjaer S, Villa LL. Chapter 5. Updating the natural history of HPV and anogenital cancer. Vaccine. 2006;24(suppl 3):S42-51.
8. Schiffman M, Herrero R, Desalle R, Hildesheim A, Wacholder S, Rodriguez AC, et al. The carcinogenicity of human papillomavirus types reflects viral evolution. Virology. 2005;337(1):76-84.
9. Schiffman M, Castle PE, Jeronimo J, Rodriguez AC, Wacholder S. Human papillomavirus and cervical cancer. Lancet. 2007;370:890-907.
10. Smith JS, Lindsay L, Hoots B, Keys J, Franceschi S, Winer R, et al. Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. Int J Cancer. 2007;121:621-32.
11. Muñoz N, Castellsagué, de Gonzáles AB, Gissman L. Chapter 1. HPV in the etiology of human cancer. Vaccine. 2006;24(suppl 3):1-10.
12. Schiller JT, Lowy DR. Prospects for cervical cancer prevention by human papillomavirus vaccination. Cancer Res. 2006;66:10229-32.
13. Hildesheim A, Herrero R, Wacholder S, Rodriguez AC, Solomon D, Bratti MC, et al. Effect of human papillomavirus 16/18 L1 virus-like particle vaccine among young women with pre-existing infection. JAMA. 2007;298:743-53.
14. Koutsky LA, Harper DM. Current findings from prophylactic vaccine trials. Vaccine. 2006;24(suppl 3):114-21.
15. The Future II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med. 2007;356:1928-43.
16. Harper DM, Franco EL, Wheeler CM, Moscicki AB, Romonowski B, Roteli-Martins CM, et al. Sustained efficacy up to 4-5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet. 2006;367:1247-55.
17. Garland SM, Hernandez-Avila M, Wheeler CM, Perez G, Harper DM, Leodolter S, et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med. 2007;356(19):1928-43.
18. Paavonen J, Jenkins D, Bosch FX, Naud P, Salmerón J, Wheeler CM, et al. Efficacy of a prophylactic adjuvant bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet. 2007;369(9580):2161-70.
19. Elmar AJ, Leodolter S, Hernandez-Avila M, Wheeler CM, Perez G, Koutsky LA, et al. Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) virus-like particle vaccine against high-grade vulvar and vaginal lesions: a combined analysis of three randomised clinical trials. Lancet. 2007;369:1693-702.
20. Crosbie EJ, Kitchener HC, Cervarix TM. A bivalent L1 virus-like particle vaccine for prevention of human papillomavirus type 16- and 18-associated cervical cancer. Expert Opin Biol Ther. 2007;7:391-6.
21. Goldie S, Kohli M, Grima D, Weinstein MC, Wright TC, Bosch FX, et al. Projected benefits of a human papillomavirus 16/18 vaccine. J Natl Cancer Inst. 2004;96:604-15.
22. Kjær SK, Hogdall E, Frederiksen K, Munk C, van den Brule AJC, Svare E, et al. The absolute risk of cervical abnormalities in high-risk human papillomavirus positive, cytologically normal women over a 10-year period. Cancer Res. 2006;66:10630-6.
23. Khan MJ, Castle PE, Lorincz AT, Wacholder S, Sherman M, Scott DR, et al. The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice. J Natl Cancer Inst. 2005;97:1072-9.
24. Vaksiner mot humant papillomavirus (HPV). Vurdering av effekt av profylaktiske HPV-vaksiner Rapport fra Kunnskapssenteret Nr 5-2007, Medisinsk metodevurdering.
25. National Board of Health. Reduction in the risk of cervical cancer by vaccination against human papillomavirus (HPV) - a health technology assessment. Copenhagen: Danish Centre for Health Technology Assessment. Available online at: http://www.sst.dk/publ/Publ2007/MTV/HPV/HPV_vaccination_en.pdf
26. Dillner J, Andrea B, Westermark B. Svensk konsensus om vaccination mot cervixcancer. Läkartidningen. 2006;103: 3377-9. English summary availabe online at: http://Itarkiv.lakartidningen.se